Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
Related Content
